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Background: Neoadjuvant chemotherapy (NACT) for the treatment of muscle-invasive bladder cancer (MIBC) remains underutilized in
the United States despite evidence supporting its use.
Objectives: To examine the perioperative chemotherapy management of patients with MIBC by medical oncologists (MedOncs) to move
toward standardization of practice
Participants and methods: A 26-question survey was emailed to 92 MedOncs belonging to the Bladder Cancer Advocacy Network or
the American Society of Clinical Oncology for completion from May to October 2011
Results: A total of 83 MedOncs completed the survey: 52% were based in academic centers. Most referrals were from urologists (79%).
NACT for treatment of MIBC and high-grade upper-tract urothelial carcinoma is offered by 80% and 46% of respondents, respectively.
Adjuvant chemotherapy for treatment of MIBC and upper-tract urothelial carcinoma is offered by 46% and 42% of respondents,
respectively. NACT was not offered by 49%, 29%, and 35% of respondents if Eastern Cooperative Oncology Group performance status was
3 or greater, if patients had T2 lesions without lymphovascular invasion, and if the glomerular ﬁltration rate waso50 ml/min, respectively.
Chemotherapy regimens included gemcitabine/cisplatin (90%), methotrexate/vinblastine/adriamycin/cisplatin (30%), dose-dense methotrex-
ate, vinblastine, adriamycin, and cisplatin (20%), and gemcitabine/carboplatin (37%).
Conclusions: Most MedOncs (79%) in this survey offer perioperative chemotherapy to all patients with MIBC. This increased use of
NACT is higher than previously reported, suggesting an increase in the adoption of recommendations that follow best evidence.
Published by Elsevier Inc.
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In the United States (US), more than 70,000 patients in
2013 presented with bladder cancer and more than 15,000
died of metastatic disease [1,2]. Approximately 20% to 25%
of patients have muscle-invasive bladder cancer (MIBC),
which has a high rate of disease progression, because
50% harbor micrometastatic disease that is not detectable
by conventional imaging. Therefore, although patients
undergo radical cystectomy, half of the patients relapse
and die of metastatic disease. MIBC is potentially curable,
but often fatal without effective treatment strategies. Opti-
mal management of MIBC mandates a multidisciplinary
approach with coordination of care between radiologists,
pathologists, urologists, medical oncologists (MedOncs),
and in some cases radiation oncologists for staging, multi-
modality treatment, and follow-ups.
Although radical cystectomy alone may lead to a durable
cure in MIBC, the high rate of tumor recurrence suggests
that early institution of systemic therapy is necessary to
improve overall survival (OS) [3,4]. In MIBC, neoadjuvant
chemotherapy (NACT) administered with deﬁnitive local
therapy has been extensively evaluated in the hopes of
improving OS. The long-term results of the international,
multicenter, phase III European Organisation for Research
and Treatment of Cancer (EORTC)/Medical Research
Council trial that randomized 976 patients to receive 3
cycles of neoadjuvant cisplatin, methotrexate, and vinblas-
tine or no NACT showed an absolute survival beneﬁt of
5% and a relative reduction in the risk of death
of 16% at 10 years [5]. The randomized Southwest
Oncology Group (SWOG) 8710 trial also showed the
median survival to be 77 months in patients with MIBC
receiving neoadjuvant methotrexate/vinblastine/adriamycin/
cisplatin (MVAC) followed by radical cystectomy, com-
pared with 46 months for patients having radical cystec-
tomy alone; a beneﬁt in median survival from NACT of 2.5
years [6]. A meta-analysis of 3,005 patients with MIBC
who received cisplatin-based NACT, including patients in
the EORTC/Medical Research Council and SWOG studies,
conﬁrmed an absolute survival beneﬁt of 5% and a 14% risk
reduction in mortality at 5 years [7].
Given the level 1 evidence of a survival beneﬁt conferred
by cisplatin-based NACT, it would be expected that the use
of NACT for the treatment of MIBC would be widely
implemented by urologists and MedOncs. The National
Comprehensive Cancer Network (NCCN) guidelines
strongly support the use of cisplatin-based combination
NACT for the treatment of MIBC with category 1 evidence.
However, multiple retrospective studies (before 2003) using
the Surveillance, Epidemiology and End Results–Medicare
database or the National Cancer Database report a low use
of perioperative chemotherapy (11%–12%), with NACT
used ino2% of patients with MIBC [8,9]. A report
documented a higher use in patients having lesions of
higher T categories [10]. Unfortunately, even when NACTwas given, cisplatin was usually not included. Although,
practice patterns may take years to change after level 1 data
have been reported, it appears that evidence-based practice
change is not occurring in MIBC. A report of patients with
MIBC managed at 15 institutions between 2003 and 2008
found that only 34% received perioperative chemotherapy,
of which 14% was NACT and only 11% was cisplatin
based [11]. A review of 17,330 cases from the Italian
National Cancer Database (2003–2007) found that only 9%
had received NACT for the treatment of MIBC before
undergoing radical cystectomy [12]. Although there was a
modest increase in NACT use from 6% in 2003 to 13% in
2007, these reports highlight the consistent underutilization
of NACT for the treatment of MIBC.
The primary goal of this study was to understand the
practice patterns of both academic and community
MedOncs treating MIBC in the United States, including
the frequency of use and type of NACT and adjuvant
chemotherapy (ACT) administered, the diagnostic studies
performed, and posttreatment follow-up.2. Participants and methods
2.1. Survey
This study was approved by the US Ofﬁce of Manage-
ment and Budget (0925-0046). To ensure a mix of
experiences and perspectives, participants were from both
larger academic medical centers and smaller community-
based practices. An electronic 26-question, secure, non-
identiﬁable link to a web-based survey was emailed to 92
MedOncs belonging to the Bladder Cancer Advocacy
Network or the American Society of Clinical Oncology
and was also posted on the “US Oncology Portal” from
May to October 2011. The US Oncology Portal is part of
the I Know Med electronic medical record shared by more
than 2,000 community oncologists in the US Oncology
network.
Patient treatment patterns were analyzed based on type
of clinical practice, referral information, type of primary
tumor (bladder cancer vs. upper-tract urothelial carcinoma
[UTUC], stage, age, renal function, and performance status
[PS]). These data were cross-tabulated with treatment and
management strategies, including frequency of use, type
and dose of NACT and ACT, and imaging and diagnostic
studies (computed tomography [CT] of the abdomen and
pelvis, CT of the chest, ultrasound, technetium-99m bone
scan, chest radiograph, magnetic resonance imaging, posi-
tron emission tomography (PET) scan, and urine cytology)
at baseline and on follow-up.
The operating settings for the web survey were set up to
accept only a single response (i.e., 1 survey) from 1
computer. The only identiﬁable information collected was
the Internet Protocol address. Participants were not provided
with consent forms. However, the following language was
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Oncology Portal” as an alternate for the consent form: “By
clicking on the link below, you are consenting to participate
in this survey.”
2.2. Analysis
A wide variety of parameters were measured. All results
are reported using percentages and descriptive analysis.
Percentages are based on the fraction that responded to a
given question.3. Results
3.1. Demographics
In total, 83 MedOncs completed 475% of the survey;
48% practiced in a community setting and 52% in an
academic setting. Demographics of the responders and their
corresponding patients with bladder cancer are in Table 1.
Fig. 1 displays the percentage of responders who offer
NACT or ACT or both for the treatment of MIBC and
patients with high-grade UTUC.
3.2. Use of perioperative chemotherapy
Fig. 2 shows the distribution of the results in Fig. 1
among academic vs. community MedOncs. Fig. 3 shows
the average distribution of NACT vs. ACT given for the
treatment of MIBC between both the groups. The collated
results comparing the use of NACT in patients with MIBC
with the use of NACT in patients with UTUC and ACT in
patients with MIBC or UTUC showed that the MedOncs
who offer NACT to eligible patients with MIBC do not
offer it to everyone with UTUC (27% offer it only some-
times and 10% do not offer it all) and are split in the use of
ACT for primary MIBC and UTUC between offering it to
everyone and offering only sometimes to high-risk patients
(data are not shown).
Fig. 4 shows the percentage of MedOncs who do not
offer NACT based on certain PS, age, or renal function.
Physicians were also asked about clinical T category and
lymph node (LN) status at presentation in their decision
making. Overall, 29% did not offer NACT to patients with
T2 lesions without lymphovascular invasion and 22% did
not offer NACT to patients with T4b lesions (data not
shown). In terms of LN status, more than 50% of physicians
do not recommend NACT if there is evidence of regional
involvement. Instead, physicians suggested that patients
with nodal involvement should be treated as having
metastatic disease with 6 cycles of chemotherapy and
considered for postchemotherapy radical cystectomy, only
if there was a response to chemotherapy (data not shown).
The average time interval between the ﬁnal dose of NACT
and radical cystectomy is 4 to 6 weeks in 92% ofresponders (data not shown). Fig. 5 shows the adjustments
made by MedOncs in patients with renal insufﬁciency and
how patients with pathologic residual disease are managed.
Table 2 lists the most common chemotherapy regimens
used. The doses commonly used were cisplatin 70 mg/m2,
gemcitabine 1,000 mg/m2, carboplatin area under the curve
of 5 mg/ml/min, and paclitaxel 175 mg/m2.
3.3. Staging modalities
Table 3 lists the staging and follow-up modalities
required by MedOncs in the management of patients with
MIBC undergoing NACT; 78% of MedOncs restage only
after NACT completion and not during NACT.4. Discussion
This is the ﬁrst survey to examine practice patterns in the
management of MIBC among MedOncs in the United
States. In contrast to previous reports from cancer databases
[10–12], the results of this survey suggest greater adoption
of level 1 evidence with 98% of MedOncs indicating they
would offer NACT. However, patient selection for NACT
occurs frequently with 18% of physicians offering NACT
only to patients with “high-risk” MIBC based on speciﬁc
tumor characteristics. Fewer physicians offer NACT for the
treatment of UTUC, but ACT is very frequently offered by
MedOncs for the treatment of both MIBC and UTUC. This
practice pattern likely represents referral patterns in which
medical oncology consults occur after patients have under-
gone radical cystectomy.
Patient factors play a greater role in decision making than
do tumor-speciﬁc factors. Moreover, concerns about cisplatin
toxicity may be one of the factors that accounts for the gap
between previously published reports, suggesting underutili-
zation of NACT and the results of this survey. As indicated
(Fig. 4), 49% of respondents do not offer NACT if the
ECOG PS was43, 35% if the glomerular ﬁltration rate
(GFR) iso50 ml/min, and 16% if the patient is older than
80 years. Age was not considered a determining factor by
61%. Previously published data have demonstrated that pre-
existing renal impairment signiﬁcantly affects the willingness
to administer perioperative cisplatin-based chemotherapy to
patients with MIBC [13], and those concerns are reﬂected in
these data. Therefore, although more MedOncs are offering
cisplatin-based NACT, an older patient population with
frequent renal insufﬁciency at risk for renal toxicity highly
inﬂuences treatment recommendations.
In patients with MIBC who have renal insufﬁciency,
MedOncs were equally divided among (1) splitting the dose
of cisplatin over 2 days, (2) substituting cisplatin with
carboplatin, or (3) recommending radical cystectomy with-
out NACT. Splitting cisplatin over 2 days, by giving
cisplatin 35 mg/m2 on days 1 and 8 has been studied in a
phase I/II trial, and it showed an overall response rates (RR)
Table 1
Patient and medical oncology practice characteristics
Patient and practice characteristics All medical
oncologist
Type of practice




n ¼ 44 (53%) n ¼ 39 (47%)
Proportion of practice dedicated to genitourinary (GU) cancer
450% 39 (46%) 35 (80%)* 3 (8%)*
25%–50% 4 (5%) 1 (2%) 3 (8%)
10%–25% 22 (26%) 5 (11%) 17 (43%)
o10% 19 (23%) 3 (7%) 17 (43%)
No response 0 0 0
Number of MIBC referred to your practice last year
420 25 (31%) 22 (50%)* 3 (8%)*
13–20 14 (18%) 9 (20%) 5 (14%)
6–12 19 (24%) 6 (14%) 13 (36%)
1–5 22 (28%) 7 (16%) 15 (42%)
No response 4 0 4
What do you estimate to be the relative contribution of each of the following in your bladder cancer referrals?
Referral source: median (range) for each category
Urologist 80% (20%–100%) 80% (25%–100%) 80% (20%–100%)
Other medical oncologist 10% (0%–75%) 10% (0%–75%) 15% (0%–75%)
Family physician or internist 5% (0%–50%) 5% (0%–20%) 10% (0%–50%)
Radiation oncologist 10% (0%–50%) 10% (0%–50%) 10% (0%–50%)
Other 0% (0%–20%) 0% (0%–15%) 0% (0%–20%)
No response 4 0 4
Age distribution of MIBC patients: median (range) for each category
o50 y 5% (0%–50%) 5% (0%–50%) 10% (0%–25%)
50–64 y 30% (0%–100%) 30% (0%–100%) 30% (0%–80%)
65–84 y 50% (0%–100%) 55% (0%–85%) 55% (0%–100%)
485 y 5% (0%–60%) 5% (0%–20%) 10% (0%–60%)
No response 4 0 4
T-stage distribution of MIBC referred to your practice: median (range) for each
category
T2: invades muscle 40% (5%–100%) 30% (5%–80%) 50% (15%–100%)
T3: invasion of perivesical tissue 30% (10%–85%) 30% (10%–85%) 30% (10%–70%)
T4a: invasion of adjacent organs 10% (3%–50%) 10% (3%–50%) 10% (5%–30%)
T4b: invasion of pelvic/abdominal wall 7.5% (2%–30%) 5% (0%–20%) 10% (0%–30%)
T (any) N (any): lymph node involvement 10% (5%–90%) 10% (5%–60%) 20% (5%–90%)
T (any) M1: metastatic disease 10% (0%–60%) 5% (1%–50%) 17.5% (0%–60%)
No response 16 0 16
*Po 0.0001 by exact 2-tailed Cochran-Armitage test for trend, comparing distribution between academic and community medical oncologists.
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OS of 16 months [14]. A large ongoing Cancer and
Leukemia Group B 90601 phase III trial evaluating the
efﬁcacy of bevacizumab with gemcitabine and cisplatin
(GC) allows patients with mild-moderate renal insufﬁciency
(GFR ¼ 40–50 ml/min) to receive split-dose cisplatin
providing an opportunity for a subset analysis of tolerance
and efﬁcacy (NCT00942331). In bladder cancer, carbopla-
tin is clearly inferior to cisplatin in terms of both CR and
OS [15–18]; in the SWOG phase II (S0219) study, 3 cycles
of neoadjuvant paclitaxel, gemcitabine, and carboplatin
showed a 60% rate of persistent cancer at radical cystec-
tomy, despite a documented clinical CR on cystoscopy [19].
This survey highlights the need for improvement in the
choice of NACT, pretreatment staging, and follow-upmodalities. GC is the NACT of choice in 90% of surveyed
MedOncs with 4 cycles given on a 21-day schedule or 3 to 4
cycles on a 28-day schedule being the favored regimens. The
second most preferred combination, by 37% of respondents,
was 3 or 4 cycles of gemcitabine and carboplatin, despite a
lack of evidence. Other, cisplatin-based preferences included
3 cycles of MVAC (30%) and 4 cycles of dose-dense (dd)
MVAC (20%). It is important to note that the most
commonly used regimens for NACT do lack level I
evidence. The data supporting the use of GC are extrapolated
from a randomized phase III trial that compared MVAC vs.
GC in 405 patients with metastatic-urothelial carcinoma.
There was no difference in median OS, time to progression,
or RR between the arms, but GC showed a more favorable
safety proﬁle with less neutropenic fever, neutropenic sepsis,
Fig. 1. Percentage of responses to questions about perioperative chemotherapies in bladder cancer and patients with upper-tract urothelial cancer. (A) Do you
offer neoadjuvant chemotherapy? (B) Do you offer neoadjuvant chemotherapy to patients with upper-tract (renal pelvis or ureter) urothelial cancer? (C) Do
you offer adjuvant chemotherapy? (D) Do you offer adjuvant chemotherapy to patients with upper-tract (renal pelvis or ureter) urothelial cancer? (Color
version of ﬁgure is available online.)
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dd-MVAC is also extrapolated from the EORTC 30924 trial
performed in metastatic urothelial carcinoma [20,21]. This
randomized phase III trial compared dd-MVAC plus gran-
ulocyte colony-stimulating factor with classic MVAC andFig. 2. Percentage of responses to questions about perioperative chemotherapies i
academic vs. community participants. (A) Do you offer neoadjuvant chemotherap
(renal pelvis or ureter) urothelial cancer? (C) Do you offer adjuvant chemotherapy?
pelvis or ureter) urothelial cancer? (Color version of ﬁgure is available online.)showed that dd-MVAC plus granulocyte colony-stimulating
factor had less neutropenic fever and higher overall RR,
including a 25% CR, but no advantage in the median OS.
Given the shorter duration of this regimen and high CR rate
in metastatic disease, this is a reasonable neoadjuvantn bladder cancer and patients with upper-tract urothelial cancer, divided by
y? (B) Do you offer neoadjuvant chemotherapy to patients with upper-tract
(D) Do you offer adjuvant chemotherapy to patients with upper-tract (renal
Fig. 3. The estimated relative distribution of perioperative chemotherapies. (Color version of ﬁgure is available online.)
Fig. 5. (A) Adjustments of chemotherapy for renal insufﬁciency. (B) Management of pathologic residual disease after neoadjuvant chemotherapy. (Color
version of ﬁgure is available online.)
Fig. 4. When do you NOT give neoadjuvant chemotherapy? (n ¼ 68). (A) At what functional status would you NOT recommend neoadjuvant
chemotherapy? (B) At what GFR value would you NOT recommend neoadjuvant chemotherapy? (C) At what age would you NOT recommend neoadjuvant
chemotherapy? (Color version of ﬁgure is available online.)
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randomized phase 2 trial comparing neoadjuvant dd-MVAC
vs. standard-dose GC in patients with MIBC, while also eva-
luating a tissue biomarker reported to be predictive of chemo-
therapy sensitivity. Based on the current limited data and
the lack of proven survival beneﬁt from carboplatin-basedcombinations, patients with MIBC who are ineligible for
cisplatin and cannot tolerate split-dose cisplatin are recom-
mended to proceed directly to radical cystectomy without
NACT [22].
In managing patients with residual disease after NACT,
25% of MedOncs report offering additional ACT,
Table 2
Chemotherapy regimens: “If you use any of the following neoadjuvant





used number of cycles
(n, %)
Gemcitabine/cisplatin D1,
8 of 21-d cycle
56 (89%) 4 cycles (40, 63%)
Gemcitabine/carboplatin 23 (37%) 4 cycles (14, 22%)
Gemcitabine/cisplatin D1,
8, 15 of 28-d cycle
20 (32%) 3 cycles (12, 19%)
MVAC 18 (29%) 3 cycles (12, 19%)
Dose-dense MVAC 12 (19%) 4 cycles (10, 16%)
Gemcitabine/single agent 6 (10%) 6 cycles (3, 5%)
Other (carboplatin/paclitaxel) 2 (4%) 3 cycles (2, 3%)
Table 3
Preference of tests for initial staging and follow-up staging
Initial staging no.
of respondents
(n ¼ 68, (%)
Follow-up staging
no. of respondents
(n ¼ 63, (%)
CT abdomen and
pelvis
61 (90%) 51 (81%)
CT chest 49 (72%) 25 (40%)
Cystoscopy Not asked 19 (30%)
Bone scan 26 (38%) 4 (5%)
PET/CT scan 14 (21%) 8 (12.7%)
Chest x-ray 11 (16%) 4 (6%)
MRI abdomen and
pelvis
10 (14%) 2 (3%)
Urine cytology 1 (1%) 2 (3%)
Ultrasound of
abdomen and pelvis
0 (0%) 0 (0%)
MRI ¼ magnetic resonance imaging; PET ¼ positron emission
tomography.
A.B. Apolo et al. / Urologic Oncology: Seminars and Original Investigations 32 (2014) 637–644 643radiotherapy, or a clinical trial. Residual disease status
following NACT is a strong negative prognostic factor
[6,23–25]. Although the 5-year survival rate was more than
85% in patients with pT0 status in the phase III INT0080
trial, it was less than 40% in patients with residual muscle-
invasive disease (4pT2) at the time of radical cystectomy
in both arms [6]. In a retrospective analysis of 37 patients
with positive pelvic LN after NACT, those receiving a
variety of “adjuvant” regimens had improved recurrence-
free and disease-speciﬁc survival [26]. Despite the poor
prognosis in patients with residual disease following NACT
and radical cystectomy, there is no high-level evidence
supporting additional ACT. A clinical trial is highly
desirable and needed in this setting.
This survey also highlights the lack of standardized
practice for staging and follow-up. The NCCN guideline
recommends imaging of the chest, abdomen, and pelvis as
initial staging and for follow-up of patients with MIBC.
Although almost all MedOncs image the abdomen and
pelvis, a lower percentage are routinely imaging the chest
with a CT. MIBC is a systemic disease with high metastatic
potential, and it is logical that a CT chest should be the test
of choice to rule out pulmonary metastasis before initiating
chemotherapy or proceeding with deﬁnitive therapy. The
disparity in practice likely reﬂects the lack of a prospective
study conﬁrming the utility of CT chest in staging, despite
NCCN recommendations. Lastly, ﬂuorodeoxyglucose–PET/
CT is a good adjunct to standard imaging with a sensitivity
of 87% and a speciﬁcity of 88% reported in the detection of
metastases in patients with bladder cancer. However, it
should not be used as the only staging modality without a
high-resolution CT or magnetic resonance imaging [27].
The intention of this study was to perform an explor-
atory analysis of the patterns of practice of MedOncs
treating patients with MIBC using a survey methodology.
Surveys are excellent methods of collecting a broad range
of data from a large number of respondents. However,
limitations include recall biases and inaccuracies in
answers. Respondents often skip questions; consequentlydifferent denominators for each question may cause
confusion in reported results. Lastly, this survey targeted
MedOncs interested in genitourinary oncology and for
whom there may be an inherent treatment bias.
5. Conclusion
Although review of older bladder cancer databases
suggests underutilization of perioperative chemotherapy,
most academic and community MedOncs do offer perioper-
ative chemotherapy to eligible patients with MIBC, with a
trend in favor of cisplatin-based NACT over ACT, recom-
mendations that follow best evidence. The most common
reasons for not recommending NACT were PS43 and
renal insufﬁciency (GFRo 50 ml/min). Age was not
considered a determining factor by most respondents. These
data suggest that MedOncs utilization of perioperative
chemotherapy for MIBC may be increasing owing to the
adoption of evidence-based recommendations. However,
multimodality treatment of MIBC also requires active
participation of urologists, and a parallel survey of urolo-
gists' referral patterns for NACT in patients with MIBC is
clearly warranted.
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